SP-MHCI-0884-2

Human ADP-dependent glucokinase  299-307, ASMTNMELM

US$169.00

In stock

Description

About Human ADP-dependent glucokinase  299-307, ASMTNMELM

The Human ADP-dependent glucokinase (mutated sequence of ASMTNRELM) Peptide (IEDB: 1074356) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The ADP-dependent glucokinase Peptide, H-ASMTNMELM-OH (Uniprot: Q9BRR6 aa:  299-307) from JPT is produced under strict quality control and quality management.

Human ADP-dependent glucokinase  299-307, ASMTNMELM - Specifications

  • Peptide sequence: H-ASMTNMELM-OH
  • Amount: 1 mg
  • Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
  • Counterion: TFA
  • Delivery Format: Freeze-dried in glass vial
  • Application(s): T-cell Immunity
  • Condition(s)/Topic(s): Cancer
  • Standard Delivery Time: approx. 3 weeks

JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!

Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Human ADP-dependent glucokinase  299-307, ASMTNMELM

References:
Read References with JPT’s Antigen Peptides
Human ADP-dependent glucokinase  299-307, ASMTNMELM has been described in:
Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy., Nat Commun, 2017 (PMID: 29133898)
The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice., Cancer Immunol Immunother, 2020 (PMID: 32561966)

Documentation

Documentation for Human ADP-dependent glucokinase  299-307, ASMTNMELM

Properties

Properties of Human ADP-dependent glucokinase  299-307, ASMTNMELM

Properties Values
Application: T-cell immunity
Category: Antigen Peptides
Condition / Topic: Cancer
Layout: Freeze-dried in glass vial
Organism: Human
Protein Name: ADP-dependent glucokinase
Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
Quantification: No, Yes

Further Information to Human ADP-dependent glucokinase  299-307, ASMTNMELM

Information Values
Sequence: H-ASMTNMELM-OH
WT Sequence: ASMTNRELM
Specifications: 9mer peptide as TFA salt
Loading...

Check our list of products, click and go.

Get a quote